Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Robin, Joyce"'
Autor:
William F. Maguire, Paul H. Haley, Catherine M. Dietz, Mike Hoffelder, Clara S. Brandt, Robin Joyce, Georgia Fitzgerald, Christopher Minnier, Cindy Sander, Laura K. Ferris, Gyorgy Paragh, Joshua Arbesman, Hong Wang, Kevin J. Mitchell, Ellen K. Hughes, John M. Kirkwood
Publikováno v:
JID Innovations, Vol 3, Iss 2, Pp 100181- (2023)
The documentation of the change in the number and appearance of pigmented cutaneous lesions over time is critical to the early detection of skin cancers and may provide preliminary signals of efficacy in early-phase therapeutic prevention trials for
Externí odkaz:
https://doaj.org/article/7cbb1b859fca45d18e5b872a007ca00b
Publikováno v:
Journal of Food Measurement and Characterization. 17:2821-2829
Publikováno v:
ACS Applied Electronic Materials. 4:5922-5932
Publikováno v:
ACS Applied Electronic Materials. 4:4863-4872
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
Purpose: A multiple myeloma vaccine has been developed whereby patient-derived tumor cells are fused with autologous dendritic cells, creating a hybridoma that stimulates a broad antitumor response. We report on the results of a phase II trial in whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::008e112b659829c9a6b5df166a140425
https://doi.org/10.1158/1078-0432.c.6522116
https://doi.org/10.1158/1078-0432.c.6522116
Autor:
David Avigan, Donald Kufe, Kenneth Anderson, Jacob Rowe, Viki Held, Lina Bisharat, Yan Emily Yuan, Vassiliki Boussiotis, Noopur Raje, Jacob Laubach, Paul Richardson, Dimitrios Tzachanis, James D. Levine, Robin Joyce, Edie Weller, Federico Campigotto, Heidi Mills, Poorvi Somaiya, Bimalangshu R. Dey, Tami Katz, Nikhil C. Munshi, Lynne Uhl, Baldev Vasir, Irit Avivi, Jacalyn Rosenblatt
PDF file - 522K, Percentage of CD8+T cells recognizing MUC1 tetramer in HLA 2.1+ patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04bf3b43e4e929fad1e7ca4d48bfe971
https://doi.org/10.1158/1078-0432.22451159.v1
https://doi.org/10.1158/1078-0432.22451159.v1
Autor:
Anita G. Koshy, Haesook T. Kim, Jessica Liegel, Jon E. Arnason, Vincent T. Ho, Joseph H. Antin, Robin Joyce, Corey S. Cutler, Mahasweta Gooptu, Sarah Nikiforow, Emma K. Logan, Pavania Elavalakanar, Michele Narcis, Dina Stroopinsky, Zachary M. Avigan, Leora Boussi, Susan L Stephenson, Hassan El Banna, Poorva Bindal, Giulia Cheloni, David E. Avigan, Robert J. Soiffer, Jacalyn Rosenblatt
Publikováno v:
Blood.
Steroid-refractory chronic graft versus host disease (cGVHD) remains a significant cause of morbidity and mortality following allogeneic transplantation. Abatacept is a selective co-stimulation modulator, used for the treatment of rheumatologic disea
Autor:
Nadia Khan, Stefan K. Barta, Ying Yuan, Robin Joyce, Jason R. Westin, Sarah C. Rutherford, Silvia Senese, Jeremy S. Abramson, Nancy L. Bartlett, Trisha Ali-Shaw, John P. Leonard, Kami J. Maddocks
Publikováno v:
The Lancet Haematology. 8:e818-e827
Background Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) is a front-line treatment for patients with aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rea
Autor:
Reid W Merryman, Robert A Redd, Eleanor Taranto, Gulrayz Ahmed, Erin Jeter, Kristin M McHugh, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Arnold S. Freedman, Eric D. Jacobsen, Caron A. Jacobson, Austin I Kim, Ann S. LaCasce, Samuel Y. Ng, Oreofe O Odejide, Erin M. Parry, Heather Jacene, Hyesun Park, Parastoo B. Dahi, Yago Nieto, Robin Joyce, Yi-Bin Chen, Margaret A. Shipp, Alex F. Herrera, Philippe Armand
Publikováno v:
Blood Advances.
Improved biomarkers are needed to guide the optimal use of autologous stem cell transplantation (ASCT) for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified u
Autor:
Matt Weinstock, Pavania Elavalakanar, Susan Bright, Srikanth R. Ambati, Jurriaan Brouwer‐Visser, Stephane Pourpe, Nathalie Fiaschi, Vladimir Jankovic, Gavin Thurston, Raquel P. Deering, Aafia Chaudhry, Robin Joyce, Jon Arnason
Publikováno v:
British journal of haematologyREFERENCES. 199(3)
Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Od